343.17
過往表現並非未來業績的可靠指標
Praxis Precision Medicines Inc. (NASDAQ: PRAX) is a clinical-stage biopharmaceutical company developing therapies for central nervous system disorders such as epilepsy, movement disorders, and depression. Its approach uses genetic insights and neuroscience to target underlying brain-circuit dysfunctions. Praxis’s share performance is typically driven by trial readouts, regulatory progress, and investor sentiment toward innovative CNS drug development.
最新股票文章
英伟达股票预测：第三方价格目标
自2025年年初以来，截至4月中旬，英伟达（NVDA）股价下跌约27.37%，但同比上涨26.48%。基于4月22日开盘价98.78美元，自1月初以来，英伟达股票波动显著，受到行业特定因素以及围绕美国贸易关税的更广泛股市不确定性影响。
17:42, 19 五月 2025
评分与评论
评分与评论
